Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR009257)
Formula
CYP1A2 ...
SVG example
Unclear
Reactant N-despropyl-rotigotine Product Neupro Metabolite M2
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 1A2 (CYP1A2) DME Info
Cytochrome P450 2C9 (CYP2C9) DME Info
Mephenytoin 4-hydroxylase (CYP2C19) DME Info
Cytochrome P450 2D6 (CYP2D6) DME Info
Cytochrome P450 3A4 (CYP3A4) DME Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010609 N-0923 N-0923 Metabolite M12 Unclear - Unclear N-0923 [1]
MR009255 Neupro N-despropyl-rotigotine Unclear - Unclear Neupro [2], [3]
MR009594 Rotigotine N-despropyl-rotigotine Unclear - Unclear Rotigotine [2]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010610 N-0923 Metabolite M12 N-0923 Metabolite M13 Unclear - Unclear N-0923 [1]
MR009596 N-despropyl-rotigotine N-Despropyl rotigotine glucuronide Conjugation - Glucuronidation Rotigotine [2]
MR009595 N-despropyl-rotigotine N-Despropyl rotigotine sulfate Oxidation - Sulfonation Rotigotine [2]
MR009256 N-despropyl-rotigotine Neupro Metabolite M1 Unclear - Unclear Neupro [2]
References
1 Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry
2 Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery
3 No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.